Vigabatrin causes profound reduction in serum alanine transaminase activity

Annals of Clinical Biochemistry

Volumn 33, Issue 3, 1996, Pages 257-258

  Ryan, M F ^a   Samy, A ^a   Young, J ^a  

^a NHS TAYSIDE   (United Kingdom)

Author keywords

Anticonvulsant; Liver function test

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ALANINE AMINOTRANSFERASE; PHENYTOIN; VIGABATRIN;

ARTICLE; CASE REPORT; CHILD; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EPILEPSY; HUMAN; PRIORITY JOURNAL;

EID: 0029992464     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329603300314     Document Type: Article

References (5)

1. Dulac O, Chiron C, Luna D, Cusmai R, Pajot N, Beaumon D, et al. Vigabatrin in childhood epilepsy. J Chld Neurol 1992; 6(Suppl 2): 2S30-37
2. Lippert B, Metcalf B W, Jung M J, Casara P. 4 Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Euro J Biochem 1977; 74: 441-5
3. ABPI. Data Sheet Compendium 1995-1996: 956
4. Williams A, Goldsmith R, Coakley J. Profound suppression of plasma alanine aminotransferase activity in children taking vigabatrin. Aust NZ J Med 1993; 23: 65
5. Hulsman J. The influence of vigabatrin on ALAT-activity measurements [Abstract]. Clin Chem 1993; 39: 1142